Cyclophosphamide/interferon-beta-1a
(Source: Reactions Weekly)
Source: Reactions Weekly - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
AbstractMultiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing –remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurrent accumulation of disability. Over the past three decades, disease-modifying therapies (DMTs) capable of reducing the frequency of relapses and slowing disability worseni ng have been studied and approved for use in patients with RRMS. The first DMTs were interferon-betas (IFN-βs), which were approved in the 1990s. Among them was IFN-β-1a for subcutaneous (sc) injection (Re...
Source: Neurology and Therapy - January 11, 2024 Category: Neurology Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA
CONCLUSION: Overall, the prevalence of spontaneous abortions and congenital anomalies of females exposed to IFN exposure before or during pregnancy was within the range reported for the general population. Most mothers paused IFN during pregnancy and breastfeeding. Relapse activity during pregnancy and lactation was observed to be low. These real-world data from a PSP corroborate European and Scandinavian registry data.TRIAL REGISTRATION: NCT04655222, EUPAS38347.PMID:38107443 | PMC:PMC10725088 | DOI:10.1177/17562864231214041 (Source: Adv Data)
Source: Adv Data - December 18, 2023 Category: Epidemiology Authors: Juliane Klehmet Yvonne Begus-Nahrmann Kirsi Taipale Gabriele Niemczyk Karin Rehberg-Weber Source Type: research
The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial
ConclusionAdding metformin to IFN β-1a demonstrated a potential effect on an oxidative stress marker (MDA). However, there is no statistically significant effect on immunological, MRI and clinical outcomes. We recommend larger scale studies to confirm or negate these findings.Trial registrationClinicalTrials.gov number: NCT05298670, 28/3/2022. (Source: Journal of Neurology)
Source: Journal of Neurology - December 9, 2023 Category: Neurology Source Type: research
RWD83 Epidemiological Characterization of the Current Patient Population of Multiple Sclerosis Patients Enrolled in a Patient Registry for Interferon-Beta 1a SC in Portugal
To present a current snapshot of the patient data in a registry of multiple sclerosis (MS) patients being treated with interferon-beta 1a SC (INF) in Portugal (PT). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Ribeiro, D. Pinto Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
CONCLUSIONS: We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no important difference in the occurrence of SAEs between first- and second-line drugs and between oral, injectable, or infused drugs, compared with placebo. Our review, along with other work in the literature, confirms poor-quality reporting of adverse events from RCTs of interventions. At the least, future studies should follow the CONSORT recommendations about reporting harm-related issues. To address adverse effects, fut...
Source: Cochrane Database of Systematic Reviews - November 30, 2023 Category: General Medicine Authors: Irene Tramacere Gianni Virgili Vittorio Perduca Ersilia Lucenteforte Maria Donata Benedetti Matteo Capobussi Greta Castellini Serena Frau Marien Gonzalez-Lorenzo Robin Featherstone Graziella Filippini Source Type: research
